<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04113629</url>
  </required_header>
  <id_info>
    <org_study_id>VHCRP1803</org_study_id>
    <nct_id>NCT04113629</nct_id>
  </id_info>
  <brief_title>Simplified Monitoring Myanmar SM2 Study</brief_title>
  <acronym>SM2</acronym>
  <official_title>Evaluation of Simplified HCV Diagnostics in HIV/HCV Co-infected Patients in Myanmar (Simplified Monitoring Myanmar SM2 Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kirby Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Public Health, Myanmar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kirby Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the proportion of patients with undetectable HCV RNA at 12 weeks&#xD;
      post-treatment (SVR12) following a course of DAA therapy delivered using a simplified&#xD;
      schedule of safety and virological monitoring.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 200 HIV/HCV co-infected patients who plan to commence DAA therapy at Specialist&#xD;
      Hospital Waibargi and Mingaladon, will be enrolled by simple random sampling.&#xD;
&#xD;
      In addition to standard of care medical procedures, each participant will complete a&#xD;
      questionnaire and have blood taken for standard HCV RNA testing.&#xD;
&#xD;
      They will also have a finger-stick capillary blood sample collected for a HCV point of care&#xD;
      test, using the the Xpert HCV Assay performed in the GeneXpert point of care machine.&#xD;
&#xD;
      Dried blood spot collection (DBS) for HCV core antigen and HCV RNA testing will be collected&#xD;
      as a research sample. Concordance between standard of care method and new DBS method will be&#xD;
      evaluated.&#xD;
&#xD;
      The proportion of patients reaching SVR will be calculated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 22, 2019</start_date>
  <completion_date type="Actual">December 22, 2020</completion_date>
  <primary_completion_date type="Actual">December 22, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Sequential Assignment</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with undetectable HCV RNA at 12 weeks post-treatment (SVR12)</measure>
    <time_frame>12 weeks post completion of commenced treatment</time_frame>
    <description>To evaluate the proportion of patients with undetectable HCV RNA at 12 weeks post-treatment (SVR12) following a course of DAA therapy delivered using a simplified schedule of safety and virological monitoring.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Liver Cirrhoses</condition>
  <condition>Liver Inflammation</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Sofosbuvir/Daclatasvir</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>standard DAA therapy: 12 or 24 weeks of sofosbuvir/daclatasvir</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HCV point of care machine</intervention_name>
    <description>Xpert HCV Assay performed on the GeneXpert point of care machine</description>
    <arm_group_label>Sofosbuvir/Daclatasvir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects must meet all of the following inclusion criteria to participate in this study.&#xD;
&#xD;
          1. Have voluntarily signed the consent form.&#xD;
&#xD;
          2. 18 years of age or older.&#xD;
&#xD;
          3. HCV antibody positive.&#xD;
&#xD;
          4. HIV antibody positive.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects who meet any of the exclusion criteria are not to be enrolled in this study.&#xD;
&#xD;
          1. Clinically significant illness (other than HCV) or any other major medical disorder&#xD;
             that may interfere with the subject treatment, assessment or compliance with the&#xD;
             protocol.&#xD;
&#xD;
          2. Creatinine clearance (CLcr) &lt; 30mL/min at screening.&#xD;
&#xD;
          3. Pregnant or nursing female.&#xD;
&#xD;
          4. Use of prohibited concomitant medications.&#xD;
&#xD;
          5. Inability or unwillingness to provide informed consent or abide by the study&#xD;
             requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Kirby Institute, University of New South Wales Australia</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 1, 2019</study_first_submitted>
  <study_first_submitted_qc>October 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2019</study_first_posted>
  <last_update_submitted>February 17, 2021</last_update_submitted>
  <last_update_submitted_qc>February 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

